Human Milk Oligosaccharides (HMO) Market to Reach USD 415.6 Million in 2030

NEW YORK, NEW YORK, UNITED STATES, March 7, 2022 /EINPresswire.com/ -- The global Human Milk Oligosaccharides (HMO) market size is expected to reach USD 415.6 Million in 2030 and register a revenue CAGR of 14.9% over the forecast period, according to the latest report by Reports and Data. Rapid market revenue growth of HMO is owing to its functional benefits in infant formula and various other nutritional food items as well as food supplements. Major companies in HMO market are developing new methods of production, such as separating HMO from cow milk, using expensive procedures (chemically or enzymatically synthesizing), or using microorganisms because HMOs increase immunity. Extensive availability of low-cost substrates is one of the reasons why manufacturing is becoming more cost-effective. Simple sugars are converted into HMOs by microbial cell factories, which keeps the process cost-effective.

Lack of large-scale manufacturing methods, high cost of research and development, and strict federal restrictions are expected to hamper the human milk oligosaccharides market revenue growth. The most prevalent application for the product is baby food, which serves to improve newborns' health and prevent disease by giving them the nutrients. HMOs also play a vital role in the development of the individual’s brain. As there is a broad demand for HMO, many producers, such as Inbiose NV and Abbott, employ fermentation technologies, chemical and enzymatic synthesis, and other techniques to produce human milk oligosaccharides, which drive market revenue growth of HMO. However, chemical and enzymatic synthesis processes are expensive and have low raw material availability in the market, thus hampering market revenue growth.

Some Key Highlights from the Report

Rise in number of middle-class families and working women is one of the key drivers of market revenue growth. New research suggests that health advantages of HMOs may be extended to people of all ages, tying in nicely with consumers' growing interest in probiotics or good bacteria that may help keep the human body healthy.

By type, neutral segment accounted for largest revenue share in 2021 and is expected to grow at a faster rate over the forecast period. Human milk oligosaccharides serve as prebiotics to encourage growth of good gut bacteria, as receptor analogues to inhibit pathogen binding, and as compounds that enhance postnatal brain development, among other things. The inclusion of HMO in functional foods and beverages has several advantages, including encouraging growth of beneficial microorganisms. It reduces the number of harmful germs including campylobacter, listeria, and salmonella.
Acidic HMO, in addition to neutral HMO, plays an important role as antimicrobial and antiviral agents. They protect infections in breastfed infants by blocking bacterial and viral cellular pathogens and toxins from infecting them directly by imitating cell entrance receptors. The initial ways by which HMOs may exercise their anti-infective characteristics are by imitating viral receptors to limit virus attachment to host cells or blocking virus entrance into the cell structure, as well as intracellularly by suppressing viral reproduction.

Human milk oligosaccharides market in North America accounted for largest revenue share in 2021 as many global firms develop new product lines using HMO as the main constituent in the region. One of the important reasons assisting the market to expand further in the countries in the region with numerous product releases is increasing consumer knowledge in the region regarding the health advantages of HMO in baby feeding.
Companies profiled in HMO market report include Inbiose NV, ELICITYL SA, Chr. Hansen Holding A/S, Glycom A/S, Abbott, ZuChem Inc., Glycosyn, Inc., Dextra Laboratories, DuPont (Nutrition & Biosciences), and FrieslandCampina.

For More Industry Insight, Request Sample@ https://www.reportsanddata.com/download-summary-form/1303

For the purpose of this report, Reports and Data has segmented the HMO market based on component, technology, type, application, and region:

Product Outlook (Revenue, USD Million; 2019–2030)

Fucosyllactose
Sialyllactose
Lacto-N-Tetraose
Lacto-N-Neotetraose
Technology Outlook (Revenue, USD Million; 2019–2030)

HMO Production Technology
Chemo-enzymatic synthesis
Whole-cell biocatalysis
Sialyltransferases
Glycosyltransferases
Fucosyltransferases
Separation & Analysis
Type Outlook (Revenue, USD Million; 2019–2030)

Acidic
Neutral
Application Outlook (Revenue, USD Million; 2019–2030)

Functional Food & Beverages
Infant Formula
Food Supplements
Others

Ask for a Special Discount on this Report @ https://www.reportsanddata.com/discount-enquiry-form/1303

Tushar Rajput
Reports and Data
+1 212-710-1370
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.